Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
42 results about "Clinical course" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Clinical course of study means graduate course work which that includes specialized advanced courses in human behavior and the social environment, social justice and policy, psychopathology, and diversity issues; research,; clinical practice with individuals, families, and groups; and a clinical practicum which that focuses on diagnostic, prevention ...
CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia
The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.
Owner:THE FEINSTEIN INST FOR MEDICAL RES
Susceptibility gene for human stroke: method of treatment
InactiveUS20050164220A1Less-effective and ineffectiveStroke preventionHydrolasesMicrobiological testing/measurementRisk strokeSusceptibility gene
A role of the human PDE4D gene in stroke is disclosed. Methods for diagnosis, prediction of clinical course and treatment for stroke using polymorphisms in the PDE4D gene are also disclosed.
Owner:DECODE GENETICS EHF
Composite Profiles of Cell Antigens and Target Signal Transduction Proteins for Analysis and Clinical Management of Hematologic Cancers
InactiveUS20100261204A1Increased riskDetermining prognosisDisease diagnosisBlood/immune system cellsCellular antigensTarget signal
Owner:BECKMAN COULTER INC
Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
InactiveUS20070105165A1Increased relapse riskDetermining prognosisDisease diagnosisBlood/immune system cellsCellular antigensTarget signal
The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
Owner:BECKMAN COULTER INC +4
Novel genes and markers associated to type 2 diabetes mellitus
InactiveUS20070059722A1Aggressive managementReduce caloric intakeCompound screeningApoptosis detectionGene productHaplotype
Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D using polymorphisms in the T2D risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D.
Owner:DSM IP ASSETS BV
Method for detecting the risk of and for treatment of type 2 diabetes
InactiveUS20060040293A1Less-effective and ineffectiveAvoid complicationsMetabolism disorderMicrobiological testing/measurementDiseaseBiology
A role of the human EXT2 gene in metabolic conditions such as T2D is disclosed. Methods and test kits for diagnosis, T2D risk prediction and prediction of clinical course of a metabolic condition using biomarkers related to the EXT2 gene are disclosed. Novel methods for prevention and treatment of metabolic diseases based on EXT2 gene, polypeptides and EXT2 related pathways are also disclosed.
Owner:JURILAB
Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
This invention provides methods and kits for diagnosing, ascertaining the clinical course of minimal residual disease associated with acute lymphoblastic leukemia (ALL). Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with diseases associated with ALL based on patterns of surface marker expression unique to ALL.
Owner:ST JUDE CHILDRENS RES HOSPITAL INC
Novel genes and markers in type 2 diabetes and obesity
ActiveUS20070292412A1Reducing and minimizing debilitating effectDiagnosis can be and efficient and safeOrganic active ingredientsNervous disorderDiseaseNovel gene
Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed.
Owner:DSM IP ASSETS BV
Methods for diagnosis of myelodysplastic syndromes (MDS)
ActiveUS20120028276A1Bioreactor/fermenter combinationsBiological substance pretreatmentsSurface markerRegimen
The present invention relates to methods and kits for diagnosing, ascertaining the clinical course of myelodysplastic syndrome (MDS) and ascertaining response to a therapy regimen of myelodysplastic syndrome. Specifically the invention provides methods and kits useful in the diagnosis and determination of clinical parameters associated with MDS based on surface markers unique to MDS.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Patient simulation system for medical services or diagnostic machines
A system, method, and apparatus for a patient simulator that interacts with a diagnostic or therapeutic medical device. The system includes a computing device coupled to a patient module. The patient module includes hydraulic equipment that simulates a baseline fluid interconnection with a therapeutic device. The computing device manages physical and virtual data, provides algorithmic calculations for simulating hypothetical patient vital signs, long-term clinical course, and simulates related fluid properties. The simulation system automatically executes a step-wise clinical scenario, specified in a spreadsheet format of patient conditions and equipment scenarios, that also includes audio / visual stimuli of operating room and diagnostic clinic environments, along with data recording capabilities. The therapeutic device can be a heart lung machine (HLM), an extracorporeal membrane oxygenation (ECMO) machine, an emergency cardiac life support (ECLS) device, a ventricular assist device (VAD), a dialysis machines, a hyperthermic intraperitoneal chemotherapy (HIPEC) machine, and an aortic balloon pump.
Owner:理查德·托尔曼 +1
Human stroke gene
A role of the human PDE4D gene in stroke is disclosed. Methods for diagnosis, prediction of clinical course and treatment for stroke using polymorphisms in the PDE4D gene are also disclosed.
Owner:DECODE GENETICS EHF
Heart simulation system for medical services or diagnostic machines
A system, a method, and an apparatus for a patient simulator that interacts with a diagnostic or therapeutic medical device. The system includes a computing device coupled to a patient module. The patient module includes hydraulic equipment that simulates a baseline fluid interconnection with a therapeutic device. The computing device manages physical and virtual data, provides algorithmic calculations for simulating hypothetical patient vital signs, long-term clinical course, and simulates related fluid properties. The simulation system automatically executes a step-wise clinical scenario, specified in a spreadsheet format of patient conditions and equipment scenarios, that also includes audio / visual stimuli of operating room and diagnostic clinic environments, along with data recording capabilities. The therapeutic device can be a heart lung machine (HLM), an extracorporeal membrane oxygenation (ECMO) machine, an emergency cardiac life support (ECLS) device, a ventricular assist device (VAD), a dialysis machines, a hyperthermic intraperitoneal chemotherapy (HIPEC) machine, and an aortic balloon pump.
Owner:理查德 D 小托尔曼
Method for detection of predisposition to atherosclerosis, coronary heart disease and related conditions
InactiveUS20130136726A1Efficient identificationReduce and minimize effectOrganic active ingredientsPeptide/protein ingredientsDiseaseCoronary artery disease
Heteroplasmy mitochondrial DNA (mtDNA) markers and haplotypes of susceptibility or predisposition to atherosclerosis, coronary heart disease (CHD) and subdiagnosis of atherosclerosis and CHD and related medical conditions are disclosed. The biomarkers may be selected from the following heteroplasmy makers: 652lns / del G; A1555G; C3256T; T3336C; G12315A; G13513A; G14459A; G14846A; G15059A. Methods and kits for diagnosis, subdiagnosis, and prediction of clinical course and efficacy of treatments for CHD, atherosclerosis and related phenotypes using heteroplasmy in the risk genes and loci and other related biomarkers are thus provided. Novel methods for prevention and treatment of atherosclerosis, CHD and related conditions based on the disclosed CHD genes, loci, polypeptides and related pathways are also provided.
Owner:MAS METABOLIC ANALYTICAL SERVICES
Method and kit for detecting a risk of essential arterial hypertension
InactiveUS20060110751A1Stop smokingReduce caloric intakeData processing applicationsHealth-index calculationMedicineEfficacy
Genes, SNP markers and haplotypes of susceptibility or predisposition to hypertension (HT) are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for HT using polymorphisms in the HT risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of HT. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of HT.
Owner:JURILAB
Method and kit for detecting a risk of acute myocardial infarction
InactiveUS20060099610A1Reduce operating costsImprove throughputMicrobiological testing/measurementTreatment effectGene product
Genes, SNP markers and haplotypes of susceptibility or predisposition to CHD such as AMI are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for AMI using polymorphisms in the AMI risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of AMI and CHD. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of CHD and AMI.
Owner:JURILAB
Method and Kit for the Prognosis of Mantle Cell Lymphoma
InactiveUS20120225432A1Remarkable differential expression patternImprove accuracyMicrobiological testing/measurementBiological testingMantle lymphomaGene
The method and the kit are useful as tools for classifying a patient diagnosed with mantle cell lymphoma into the category of: indolent or conventional. The method comprises: a) providing a sample from a patient suffering from mantle cell lymphoma; b) determining the level of expression of at least one gene selected from the group consisting of: RNGTT, HDGFRP3, FARP1, HMGB3, LGALS3BP, PON2, CDK2AP1, DBN1, CNR1, CNN3, SOX11, SETMAR and CSNK1E in said sample; and c) comparing the level of expression of each of the measured genes with respect to the level of expression of the same genes in a control sample; wherein the absence of expression or the underexpression of said genes with respect to the same genes in said control sample is indicative of the indolent clinical course of the MCL.
Owner:HOSPITAL CLINIC DE BARCELONA +3
Genes and markers in type 2 diabetes and obesity
ActiveUS7901885B2Reducing and minimizing debilitating effectDiagnosis can be and efficient and safeOrganic active ingredientsNervous disorderGene productHaplotype
Owner:DSM IP ASSETS BV
Electronic system for assisting the study and practice of medicine
InactiveUS20100323336A1Convenient teachingFacilitates learning processDigital data information retrievalDigital data processing detailsThird partyElectronic systems
An electronic system generates and manages multiple knowledge bases of medical students and practitioners. The knowledge bases are organized according to and for the function of specific limited medical problems. Data regarding each problem cross-references both basic sciences and clinical courses. Users are able to create their own knowledge base with the use of teaching data, their own user generated data, and third party user generated data. Data is dynamically updated, and the knowledge bases support the future medical practice of students.
Owner:ALERT LIFE SCI COMPUTING
Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
The present invention provides methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
Owner:BECKMAN COULTER INC +4
Method For Diagnosis Of Myelodysplastic Syndromes (Mds)
ActiveUS20080026406A1Bioreactor/fermenter combinationsBiological substance pretreatmentsRegimenClinical course
The present invention provides a method of diagnosing a mylodysplastic syndrome, a method of ascertaining the clinical course of a myelodysplastic syndrome or a method of ascertaining response to a therapy regimen in a subject diagnosed with a myelodysplastic syndrome, and kits for effecting the same.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Electronic health record hanging protocol and display for an integrated clinical course
Owner:ZELINA FLUENCY INC
Methods for diagnosis of myelodysplastic syndromes (MDS)
ActiveUS7879569B2Bioreactor/fermenter combinationsBiological substance pretreatmentsSurface markerRegimen
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Method for treatment of mesothelioma
InactiveUS20140294993A1Survival time is longProlong survival timeBiocideHeavy metal active ingredientsGrowth retardantTreatment choices
The present invention provides that Ras-like, estrogen-regulated, growth inhibitor (RERG) is a malignant mesothelioma biomarker of clinical course and treatment sensitivity and, itself a target for mesothelioma treatment. A low RERG level in a mesothelioma subject indicates poor prognosis. Analyzing RERG expression level along can help mesothelioma patients make treatment choices. Furthermore, mesothelioma can be treated by modulating RERG activity, for example, with treatment with estrogen or estrogen-like agents.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC
System and Method for Decision-Making for Determining Initiation and Type of Treatment for Patients with a Progressive Illness
InactiveUS20180293352A1Facilitates objectiveEasy to quantifyOrganic detergent compounding agentsSurface-active detergent compositionsMedicinePatients symptoms
A system, non-transitory computer readable medium, and method are provided for determining patient care services for a patient being treated for a life-threatening or life-limiting progressive illness. Patient symptoms are identified by receiving data comprising personal health information of a patient. The level of distress of the patient is determined by analyzing the data comprising personal health information of the patent. A score is established based on criteria comprising the level of distress of the patient and a severity of the patient symptoms. The score correlates the level of distress of the patient with a clinical course of the life-threatening or life-limiting progressive illness. One or more patient care services appropriate for the clinical course of the life-threatening or life-limiting progressive illness and the level of distress of the patient is determined based on the score.
Owner:COTA
CD38 as a prognostic indicator in B cell chronic lymphocytic leukemia
InactiveUS20070202534A1Organic active ingredientsMicrobiological testing/measurementB-cell chronic lymphocytic leukemiaGene
The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation.
Owner:THE FEINSTEIN INST FOR MEDICAL RES
Method for identifying myelodysplastic syndrome-specific genes
InactiveUS20050233330A1Efficient identificationMicrobiological testing/measurementSurface markerDisease course
Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells (HSC). Clinical course of MDS can be divided into several stages; an indolent chronic phase termed “refractory anemia (RA)” or “RA with ringed sideroblasts”, and advanced stages including “RA with excess of blasts (RAEB)” and MDS-associated leukemia. Despite a relatively high incidence of MDS, there are few effective means to treat individuals at its advanced stages. DNA microarray would be a useful tool to clarify the molecular pathogenesis of, and to develop novel treatments against, MDS. However, a simple comparison with DNA microarray of bone marrow (BM) mononuclear cells from individuals at distinct stages of MDS would mainly lead to the identification of “pseudo-positive” genes whose expression alterations only reflect the difference in the proportion of MDS blasts within BM. To efficiently analyze the stage-progression mechanism in MDS, AC133 cell surface marker-positive HSC was purified from BM of healthy volunteers as well as 30 MDS patients, and used to compare the expression profiles of 2304 genes by microarray made by the inventor. The inventor succeeded in isolating sets of genes, expression of which was specific to either indolent stage or the advanced ones.
Owner:ASTELLAS PHARMA INC
Horse multi-color organ skin-fur-skeleton connected dubbed dry specimen and manufacturing method thereof
PendingCN107545819ASolve the shortcomings of the system such as poor teaching and single functionIncrease the value of teaching reuseEducational modelsWhole bodyAnimal husbandry
The invention discloses a horse multi-color organ skin-fur-skeleton connected dubbed dry specimen. The specimen comprises a specimen body and a bench for fixing the specimen body; the specimen body ismainly composed of a prosthesis bracket, a skin-fur-skeleton connecting body, an isolated skeleton and an imitated arcus costarum; the isolated skeleton is manufactured on the prosthesis bracket in series, the skin-fur-skeleton connecting body is arranged on the prosthesis bracket through gesture adjustment, and multi-color dry cardiovascular organs, multi-color dry organs of the respiratory tract and multi-color dry organs of the digestive tract are arranged in a body cavity of the specimen body according to original positions and original shapes. According to the specimen, the skin and furof the whole body are connected, the shape is life-like, the dry specimen can have multiple application functions of display of the various multi-color organs of an animal specimen, skin-fur-skeletonconnection, dubbed playback teaching and convenient taking and storage, and can replace animal living bodies for practical teaching of clinical courses and elementary courses of animal husbandry and medical science.
Owner:JIANGSU AGRI ANIMAL HUSBANDRY VOCATIONAL COLLEGE
System and method for decision-making for determining initiation and type of treatment for patients with a progressive illness
InactiveUS20180293353A1Facilitates objective and quantitative and standardized decision makingOrganic detergent compounding agentsSurface-active detergent compositionsMedicinePatients symptoms
A system, non-transitory computer readable medium, and method are provided for determining patient care services for a patient being treated for a life-threatening or life-limiting progressive illness. Patient symptoms are identified by receiving data comprising personal health information of a patient. The level of distress of the patient is determined by analyzing the data comprising personal health information of the patent. A score is established based on criteria comprising the level of distress of the patient and a severity of the patient symptoms. The score correlates the level of distress of the patient with a clinical course of the life-threatening or life-limiting progressive illness. One or more patient care services appropriate for the clinical course of the life-threatening or life-limiting progressive illness and the level of distress of the patient is determined based on the score.
Owner:COTA
Application of aortic root forming process to Stanford A-type aortic dissection clinic surgical method
The present invention provides an application of aortic root angioplasty in Stanford type A aortic dissection clinical procedures. During the clinical treatment of Stanford type A aortic dissection, the premise of not using new surgical materials and increasing the cost of surgery It can basically eliminate the proximal dissection cavity of the aortic root, avoid anastomotic bleeding, avoid the compression of the coronary arteries by the proximal dissection cavity of the aortic root, and effectively avoid long-term false lumen caused by the proximal aortic root. There is formation of pseudoaneurysm caused by proximal neoplasia of the aortic root or anastomotic stoma. Reduce the possibility of bleeding while avoiding complications caused by massive blood transfusion, shorten the operation time, improve the success rate of the operation, reduce the difficulty of Stanford type A aortic dissection, and facilitate the promotion of Stanford type A aortic dissection and popularity.
Owner:JILIN UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com